Skip to content

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.5×0.0×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
0.3×+0.2×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-0.2×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-0.1×

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Calculated from Artiva Biotherapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s asset turnover?
Artiva Biotherapeutics, Inc. (ARTV) reported asset turnover of 0× in Q4 2025.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.